Finland · Delayed Price · Currency is EUR Remedy Entertainment Oyj Statistics
Total Valuation
HEL:REMEDY has a market cap or net worth of EUR 199.51 million. The enterprise value is 183.56 million.
| Market Cap | 199.51M |
| Enterprise Value | 183.56M |
Important Dates
The next confirmed earnings date is Tuesday, August 11, 2026.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HEL:REMEDY has 13.59 million shares outstanding. The number of shares has decreased by -6.95% in one year.
| Current Share Class | 13.59M |
| Shares Outstanding | 13.59M |
| Shares Change (YoY) | -6.95% |
| Shares Change (QoQ) | -13.02% |
| Owned by Insiders (%) | 32.80% |
| Owned by Institutions (%) | 20.88% |
| Float | 9.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 61.17 |
| PS Ratio | 3.36 |
| PB Ratio | 3.46 |
| P/TBV Ratio | 7.16 |
| P/FCF Ratio | 12.78 |
| P/OCF Ratio | 10.25 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 39.63, with an EV/FCF ratio of 11.76.
| EV / Earnings | n/a |
| EV / Sales | 3.09 |
| EV / EBITDA | 39.63 |
| EV / EBIT | n/a |
| EV / FCF | 11.76 |
Financial Position
The company has a current ratio of 3.74, with a Debt / Equity ratio of 0.31.
| Current Ratio | 3.74 |
| Quick Ratio | 3.74 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | 3.90 |
| Debt / FCF | 1.16 |
| Interest Coverage | -0.15 |
Financial Efficiency
Return on equity (ROE) is -20.63% and return on invested capital (ROIC) is -0.48%.
| Return on Equity (ROE) | -20.63% |
| Return on Assets (ROA) | -0.14% |
| Return on Invested Capital (ROIC) | -0.48% |
| Return on Capital Employed (ROCE) | -0.28% |
| Weighted Average Cost of Capital (WACC) | 9.66% |
| Revenue Per Employee | 153,279 |
| Profits Per Employee | -33,964 |
| Employee Count | 387 |
| Asset Turnover | 0.65 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -2.91M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +2.66% in the last 52 weeks. The beta is 1.05, so HEL:REMEDY's price volatility has been similar to the market average.
| Beta (5Y) | 1.05 |
| 52-Week Price Change | +2.66% |
| 50-Day Moving Average | 13.68 |
| 200-Day Moving Average | 13.94 |
| Relative Strength Index (RSI) | 53.51 |
| Average Volume (20 Days) | 9,581 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HEL:REMEDY had revenue of EUR 59.32 million and -13.14 million in losses. Loss per share was -1.02.
| Revenue | 59.32M |
| Gross Profit | 48.44M |
| Operating Income | -209,000 |
| Pretax Income | -16.05M |
| Net Income | -13.14M |
| EBITDA | 3.30M |
| EBIT | -209,000 |
| Loss Per Share | -1.02 |
Balance Sheet
The company has 34.03 million in cash and 18.08 million in debt, with a net cash position of 15.94 million or 1.17 per share.
| Cash & Cash Equivalents | 34.03M |
| Total Debt | 18.08M |
| Net Cash | 15.94M |
| Net Cash Per Share | 1.17 |
| Equity (Book Value) | 57.62M |
| Book Value Per Share | 4.84 |
| Working Capital | 30.97M |
Cash Flow
In the last 12 months, operating cash flow was 19.46 million and capital expenditures -3.85 million, giving a free cash flow of 15.61 million.
| Operating Cash Flow | 19.46M |
| Capital Expenditures | -3.85M |
| Depreciation & Amortization | 3.51M |
| Net Borrowing | -1.44M |
| Free Cash Flow | 15.61M |
| FCF Per Share | 1.15 |
Margins
Gross margin is 81.65%, with operating and profit margins of -0.35% and -22.16%.
| Gross Margin | 81.65% |
| Operating Margin | -0.35% |
| Pretax Margin | -27.06% |
| Profit Margin | -22.16% |
| EBITDA Margin | 5.56% |
| EBIT Margin | -0.35% |
| FCF Margin | 26.31% |
Dividends & Yields
HEL:REMEDY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 6.95% |
| Shareholder Yield | 6.95% |
| Earnings Yield | -6.59% |
| FCF Yield | 7.82% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for HEL:REMEDY is 16.75, which is 14.10% higher than the current price. The consensus rating is "Buy".
| Price Target | 16.75 |
| Price Target Difference | 14.10% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 10.37% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |